Form 20-F ☑
|
Form 40-F ☐
|
Yes ☐
|
No ☑
|
EXFO INC.
|
|
By: /s/ Philippe Morin
Name: Philippe Morin
Title: Chief Executive Officer
|
|
■
|
Sales increased 9.2% to US$69.2 million, above midpoint of guidance range
|
■ |
Bookings improved 23.3% to US$81.2 million, book-to-bill ratio of 1.17
|
■ |
Announced multi-million-dollar deal with a tier-1 service provider after quarter-end
|
-
|
Optical, transport and copper test solutions make up the T&M product family, including portable
equipment for the field and benchtop units for the lab and manufacturing environments. EXFO is No. 1 worldwide in optical testing and a top-2 provider of portable telecom T&M solutions.
|
-
|
The SASS family mainly consists of service assurance, fiber monitoring, analytics and professional
services as well as other systems-related solutions like network simulation and network topology discovery. EXFO is well positioned for virtualization and 5G network transformations and is now part of the top-5 global SASS
suppliers based on its acquisitions of Ontology and Astellia.
|
Three months ended November 30,
|
||||||||
2019
|
2018
|
|||||||
Test and measurement sales
|
$
|
49,764
|
$
|
50,186
|
||||
Service assurance, systems and services sales
|
19,416
|
12,968
|
||||||
Foreign exchange gains on forward exchange contracts
|
21
|
237
|
||||||
Total sales
|
$
|
69,201
|
$
|
63,391
|
||||
Test and measurement bookings
|
$
|
63,996
|
$
|
52,854
|
||||
Service assurance, systems and services bookings
|
17,221
|
12,788
|
||||||
Foreign exchange gains on forward exchange contracts
|
21
|
237
|
||||||
Total bookings
|
$
|
81,238
|
$
|
65,879
|
||||
Book-to-bill ratio (bookings/sales)
|
1.17
|
1.04
|
||||||
Gross margin before depreciation and amortization*
|
$
|
40,304
|
$
|
40,102
|
||||
58.2
|
%
|
63.3
|
%
|
|||||
Other selected information:
|
||||||||
IFRS net earnings (loss)
|
$
|
(7,467
|
)
|
$
|
2,679
|
|||
Amortization of intangible assets
|
$
|
2,940
|
$
|
1,119
|
||||
Stock-based compensation costs
|
$
|
418
|
$
|
402
|
||||
Restructuring charges
|
$
|
2,741
|
$
|
‒
|
||||
Changes in fair value of cash contingent consideration
|
$
|
‒
|
$
|
(155
|
)
|
|||
Acquisition-related deferred revenue fair value adjustment
|
$
|
864
|
$
|
‒
|
||||
Net income tax effect of the above items
|
$
|
(423
|
)
|
$
|
(172
|
)
|
||
Foreign exchange gain
|
$
|
(215
|
)
|
$
|
(1,218
|
)
|
||
Adjusted EBITDA*
|
$
|
2,728
|
$
|
6,059
|
●
|
Sales. Sales
increased 9.2% year-over-year mainly due to the Astellia acquisition (US$7.5 revenue contribution in the quarter), partially offset by a negative currency impact. Test and Measurement sales accounted for 72% of revenue in the first
quarter of 2019, while Service Assurance, Systems and Services sales totaled 28%. Revenue distribution among
the three main selling regions in the first quarter amounted to 51% in the Americas, 33% in Europe,
Middle East and Africa (EMEA) and 16% in Asia-Pacific. EXFO’s top customer accounted for 9.0%
of sales, while the top three represented 19.6%.
|
●
|
Profitability.
IFRS net loss totaled US$7.5 million in the first quarter of 2019, including US$5.1 million for newly acquired Astellia. Of that number, US$1.8 million is attributable to after-tax amortization of acquired intangible assets.
Adjusted EBITDA amounted to US$2.7 million in the first quarter of 2019.
|
●
|
Innovation. EXFO
received two separate innovation-related awards from the Metro Ethernet Forum (MEF) in the first quarter of fiscal 2019. EXFO’s software verifier agent, a software solution providing advanced layer-2 to layer-7 testing and
end-to-end visibility, received the Technology Solutions Award for Service Assurance from the MEF. EXFO also accepted a Proof of Concept Award from the MEF for its contribution to a collaborative project, named Blade Runner,
delivering augmented reality over a 5G wireless network. EXFO covered service assurance by providing virtual probes to enable closed-loop automation and seamless service continuity. EXFO had previously obtained the TM Forum
Outstanding Catalyst Innovation Award for its involvement in the Blade Runner project.
|
Three months ended
November 30,
|
||||||||
2018
|
2017
|
|||||||
IFRS sales
|
$
|
69,201
|
$
|
63,391
|
||||
Acquisition-related deferred revenue fair value adjustment
|
864
|
‒
|
||||||
Non-IFRS sales
|
$
|
70,065
|
$
|
63,391
|
Three months ended
November 30,
|
||||||||
2018
|
2017
|
|||||||
IFRS net earnings (loss) for the period
|
$
|
(7,467
|
)
|
$
|
2,679
|
|||
Add (deduct):
|
||||||||
Depreciation
|
1,429
|
1,154
|
||||||
Amortization
|
2,940
|
1,119
|
||||||
Interest and other expense
|
377
|
338
|
||||||
Income taxes
|
1,641
|
1,740
|
||||||
Stock-based compensation costs
|
418
|
402
|
||||||
Restructuring charges
|
2,741
|
‒
|
||||||
Change in fair value of cash contingent consideration
|
‒
|
(155
|
)
|
|||||
Acquisition-related deferred revenue fair value adjustment
|
864
|
‒
|
||||||
Foreign exchange gain
|
(215
|
)
|
(1,218
|
)
|
||||
Adjusted EBITDA for the period
|
$
|
2,728
|
$
|
6,059
|
||||
Adjusted EBITDA in percentage of sales
|
3.9
|
%
|
9.6
|
%
|
As at
November 30,
2018
|
As at
August 31,
2018
|
|||||||
Assets
|
||||||||
Current assets
|
||||||||
Cash
|
$
|
18,087
|
$
|
12,758
|
||||
Short-term investments
|
1,976
|
2,282
|
||||||
Accounts receivable
|
||||||||
Trade
|
50,364
|
47,273
|
||||||
Other
|
3,693
|
4,137
|
||||||
Income taxes and tax credits recoverable
|
4,694
|
4,790
|
||||||
Inventories
|
39,186
|
38,589
|
||||||
Prepaid expenses
|
5,019
|
5,291
|
||||||
Other assets
|
2,264
|
2,279
|
||||||
125,283
|
117,399
|
|||||||
Tax credits recoverable
|
47,527
|
47,677
|
||||||
Property, plant and equipment
|
43,687
|
44,310
|
||||||
Intangible assets
|
26,507
|
29,866
|
||||||
Goodwill
|
39,115
|
39,892
|
||||||
Deferred income tax assets
|
4,270
|
4,714
|
||||||
Other assets
|
661
|
686
|
||||||
$
|
287,050
|
$
|
284,544
|
|||||
Liabilities
|
||||||||
Current liabilities
|
||||||||
Bank loan
|
$
|
21,399
|
$
|
10,692
|
||||
Accounts payable and accrued liabilities
|
49,590
|
47,898
|
||||||
Provisions
|
2,338
|
2,954
|
||||||
Income taxes payable
|
557
|
873
|
||||||
Deferred revenue
|
18,564
|
16,556
|
||||||
Other liabilities
|
3,109
|
3,197
|
||||||
Current portion of long-term debt (note 5)
|
2,808
|
2,921
|
||||||
98,365
|
85,091
|
|||||||
Provisions
|
2,605
|
2,347
|
||||||
Deferred revenue
|
8,320
|
6,947
|
||||||
Long-term debt (note 5)
|
5,185
|
5,907
|
||||||
Deferred income tax liabilities
|
5,117
|
5,910
|
||||||
Other liabilities
|
540
|
421
|
||||||
120,132
|
106,623
|
|||||||
Shareholders’ equity
|
||||||||
Share capital (note 6)
|
92,580
|
91,937
|
||||||
Contributed surplus
|
18,245
|
18,428
|
||||||
Retained earnings
|
107,186
|
114,906
|
||||||
Accumulated other comprehensive loss
|
(51,093
|
)
|
(47,350
|
)
|
||||
166,918
|
177,921
|
|||||||
$
|
287,050
|
$
|
284,544
|
Three months ended
November 30,
|
||||||||
2018
|
2017
|
|||||||
Sales
|
$
|
69,201
|
$
|
63,391
|
||||
Cost of sales (1)
|
28,897
|
23,289
|
||||||
Selling and administrative
|
26,375
|
23,193
|
||||||
Net research and development
|
15,224
|
11,252
|
||||||
Depreciation of property, plant and equipment
|
1,429
|
1,154
|
||||||
Amortization of intangible assets
|
2,940
|
1,119
|
||||||
Change in fair value of cash contingent consideration
|
‒
|
(155
|
)
|
|||||
Interest and other expense
|
377
|
338
|
||||||
Foreign exchange gain
|
(215
|
)
|
(1,218
|
)
|
||||
Earnings (loss) before income taxes
|
(5,826
|
)
|
4,419
|
|||||
Income taxes
(note 8)
|
1,641
|
1,740
|
||||||
Net earnings (loss) for the period
|
$
|
(7,467
|
)
|
$
|
2,679
|
|||
Basic and diluted net earnings (loss) per share
|
$
|
(0.14
|
)
|
$
|
0.05
|
|||
Basic weighted average number of shares outstanding
(000’s)
|
55,184
|
54,805
|
||||||
Diluted weighted average number of shares
outstanding (000’s) (note 9)
|
55,184
|
55,793
|
(1)
|
The cost of sales is exclusive of depreciation and amortization, shown separately.
|
Three months ended
November 30,
|
||||||||
2018
|
2017
|
|||||||
Net earnings (loss) for the period
|
$
|
(7,467
|
)
|
$
|
2,679
|
|||
Other comprehensive income (loss), net of income taxes
|
||||||||
Items that may be reclassified subsequently to net earnings (loss)
|
||||||||
Foreign currency translation adjustment
|
(3,356
|
)
|
(4,130
|
)
|
||||
Unrealized gains/losses on forward exchange contracts
|
(687
|
)
|
(524
|
)
|
||||
Reclassification of realized gains/losses on forward exchange contracts
in net earnings (loss)
|
91
|
(383
|
)
|
|||||
Deferred income tax effect of gains/losses on forward exchange contracts
|
209
|
215
|
||||||
Other comprehensive loss
|
(3,743
|
)
|
(4,822
|
)
|
||||
Comprehensive loss for the period
|
$
|
(11,210
|
)
|
$
|
(2,143
|
)
|
Three months ended November 30, 2017
|
||||||||||||||||||||
Share
capital
|
Contributed surplus
|
Retained earnings
|
Accumulated other comprehensive loss
|
Total
shareholders’ equity
|
||||||||||||||||
Balance as at September 1, 2017
|
$
|
90,411
|
$
|
18,184
|
$
|
127,160
|
$
|
(38,965
|
)
|
$
|
196,790
|
|||||||||
Reclassification of stock-based compensation costs (note 6)
|
598
|
(598
|
)
|
‒
|
‒
|
‒
|
||||||||||||||
Stock-based compensation costs
|
‒
|
430
|
‒
|
‒
|
430
|
|||||||||||||||
Net earnings for the period
|
‒
|
‒
|
2,679
|
‒
|
2,679
|
|||||||||||||||
Other comprehensive loss
|
||||||||||||||||||||
Foreign currency translation adjustment
|
‒
|
‒
|
‒
|
(4,130
|
)
|
(4,130
|
)
|
|||||||||||||
Changes in unrealized gains/losses on forward exchange contracts, net of deferred
income taxes of $215
|
‒
|
‒
|
‒
|
(692
|
)
|
(692
|
)
|
|||||||||||||
Total comprehensive loss for the period
|
(2,143
|
)
|
||||||||||||||||||
Balance as at November 30, 2017
|
$
|
91,009
|
$
|
18,016
|
$
|
129,839
|
$
|
(43,787
|
)
|
$
|
195,077
|
Three months ended November 30, 2018
|
||||||||||||||||||||
Share
capital
|
Contributed surplus
|
Retained earnings
|
Accumulated other comprehensive loss
|
Total
shareholders’ equity
|
||||||||||||||||
Balance as at September 1, 2018
|
$
|
91,937
|
$
|
18,428
|
$
|
114,906
|
$
|
(47,350
|
)
|
$
|
177,921
|
|||||||||
Adoption of IFRS 9 (note 2)
|
‒
|
‒
|
(253
|
)
|
‒
|
(253
|
)
|
|||||||||||||
Adjusted balance as at September 1, 2018
|
91,937
|
18,428
|
114,653
|
(47,350
|
)
|
177,668
|
||||||||||||||
Reclassification of stock-based compensation costs (note 6)
|
643
|
(643
|
)
|
‒
|
‒
|
‒
|
||||||||||||||
Stock-based compensation costs
|
‒
|
460
|
‒
|
‒
|
460
|
|||||||||||||||
Net loss for the period
|
‒
|
‒
|
(7,467
|
)
|
‒
|
(7,467
|
)
|
|||||||||||||
Other comprehensive loss
|
||||||||||||||||||||
Foreign currency translation adjustment
|
‒
|
‒
|
‒
|
(3,356
|
)
|
(3,356
|
)
|
|||||||||||||
Changes in unrealized gains/losses on forward exchange contracts, net of deferred
income taxes of $209
|
‒
|
‒
|
‒
|
(387
|
)
|
(387
|
)
|
|||||||||||||
Total comprehensive loss for the period
|
(11,210
|
)
|
||||||||||||||||||
Balance as at November 30, 2018
|
$
|
92,580
|
$
|
18,245
|
$
|
107,186
|
$
|
(51,093
|
)
|
$
|
166,918
|
Three months ended
November 30,
|
||||||||
2018
|
2017
|
|||||||
Cash flows from operating activities
|
||||||||
Net earnings (loss) for the period
|
$
|
(7,467
|
)
|
$
|
2,679
|
|||
Add (deduct) items not affecting cash
|
||||||||
Stock-based compensation costs
|
418
|
402
|
||||||
Depreciation and amortization
|
4,369
|
2,273
|
||||||
Write-off of capital assets
|
‒
|
124
|
||||||
Change in fair value of cash contingent consideration
|
‒
|
(155
|
)
|
|||||
Deferred revenue
|
3,922
|
(782
|
)
|
|||||
Deferred income taxes
|
(29
|
)
|
(240
|
)
|
||||
Changes in foreign exchange gain/loss
|
(529
|
)
|
(247
|
)
|
||||
684
|
4,054
|
|||||||
Changes in non-cash operating items
|
||||||||
Accounts receivable
|
(4,052
|
)
|
1,085
|
|||||
Income taxes and tax credits
|
(998
|
)
|
59
|
|||||
Inventories
|
(1,361
|
)
|
(1,953
|
)
|
||||
Prepaid expenses
|
183
|
318
|
||||||
Other assets
|
(12
|
)
|
4
|
|||||
Accounts payable, accrued liabilities and provisions
|
3,132
|
(1,369
|
)
|
|||||
Other liabilities
|
(51
|
)
|
188
|
|||||
(2,475
|
)
|
2,386
|
||||||
Cash flows from investing activities
|
||||||||
Additions to short-term investments
|
‒
|
(234
|
)
|
|||||
Proceeds from disposal of short-term investments
|
342
|
‒
|
||||||
Purchases of capital assets
|
(2,882
|
)
|
(1,991
|
)
|
||||
Investment in an associate
|
‒
|
(10,311
|
)
|
|||||
Business combination, net of cash acquired
|
‒
|
(9,540
|
)
|
|||||
(2,540
|
)
|
(22,076
|
)
|
|||||
Cash flows from financing activities
|
||||||||
Bank loan
|
11,257
|
2
|
||||||
Repayment of long-term debt
|
(717
|
)
|
(70
|
)
|
||||
10,540
|
(68
|
)
|
||||||
Effect of foreign exchange rate changes on cash
|
(196
|
)
|
(226
|
)
|
||||
Change in cash
|
5,329
|
(19,984
|
)
|
|||||
Cash – Beginning of the period
|
12,758
|
38,435
|
||||||
Cash – End of the period
|
$
|
18,087
|
$
|
18,451
|
||||
Supplementary information
|
||||||||
Income taxes paid
|
$
|
871
|
$
|
682
|
1
|
Nature of Activities and Incorporation
|
2
|
Basis of Presentation
|
As reported
as at August 31, 2018
|
Adjustments
|
As adjusted
As at September 1, 2018
|
||||||||||
Accounts receivables – trade
|
$
|
47,273
|
$
|
(303
|
)
|
$
|
46,970
|
|||||
Income taxes recoverable
|
$
|
4,790
|
$
|
50
|
$
|
4,840
|
||||||
Total assets
|
$
|
284,544
|
$
|
(253
|
)
|
$
|
284,291
|
|||||
Retained earnings
|
$
|
114,906
|
$
|
(253
|
)
|
$
|
114,653
|
|||||
Shareholders’ equity
|
$
|
177,921
|
$
|
(253
|
)
|
$
|
177,668
|
Financial assets
|
Classification – IAS 39
|
Classification – IFRS 9
|
Cash
|
Loans and receivables
|
Amortized cost
|
Short-term investments
|
Available for sale
|
Fair value through other comprehensive income
|
Accounts receivable
|
Loans and receivables
|
Amortized cost
|
Other assets
|
Loans and receivables
|
Amortized cost
|
Forward exchange contracts
|
Derivatives used for hedging
|
Derivatives used for hedging
|
Bank loan
|
Other financial liabilities
|
Amortized cost
|
Accounts payable and accrued liabilities
|
Other financial liabilities
|
Amortized cost
|
Other liabilities
|
Other financial liabilities
|
Amortized cost
|
Long-term debt
|
Other financial liabilities
|
Amortized cost
|
Forward exchange contracts
|
Derivatives used for hedging
|
Derivatives used for hedging
|
3
|
Restructuring Charges
|
Balance – Beginning of the period
|
$
|
3,167
|
||
Additions (note 7)
|
2,741
|
|||
Payments
|
(2,984
|
)
|
||
Balance – End of the period
|
$
|
2,924
|
4
|
Financial Instruments
|
As at November 30, 2018
|
As at August 31, 2018
|
|||||||||||||||
Level 1
|
Level 2
|
Level 1
|
Level 2
|
|||||||||||||
Financial assets
|
||||||||||||||||
Short-term investments
|
$
|
1,976
|
$
|
‒ |
$
|
2,282
|
$
|
‒ | ||||||||
Forward exchange contracts
|
$
|
‒ |
$
|
37
|
$
|
‒ |
$
|
318
|
||||||||
Financial liabilities
|
||||||||||||||||
Forward exchange contracts
|
$
|
‒ |
$
|
1,271
|
$
|
‒ |
$
|
807
|
Expiry dates
|
Contractual
amounts
|
Weighted average
contractual forward rates
|
|||||||
December 2018 to August 2019
|
$
|
22,200
|
1.2969
|
||||||
September 2019 to August 2020
|
19,500
|
1.2795
|
|||||||
September 2020 to August 2021
|
5,100
|
1.2751
|
|||||||
Total
|
$
|
46,800
|
1.2873
|
Expiry dates
|
Contractual
amount
|
Weighted average
contractual forward rate
|
|||||||
December 2018 to August 2019
|
$
|
4,000
|
68.77
|
5
|
Long-term Debt
|
As at
November 30,
2018
|
As at
August 31,
2018
|
|||||||
Unsecured, non-interest-bearing loans, denominated
in euros, repayable in quarterly instalments, maturing in March 2024 and March 2025
|
$
|
909
|
$
|
883
|
||||
Unsecured loans, denominated in euros, repayable in
monthly, quarterly
or bi-annual instalments, bearing interest at annual rates of nil to 5.0%, maturing at different dates between December 2018 and September 2023 |
4,366
|
4,853
|
||||||
Loans, secured by the universality of the assets of
a subsidiary, denominated in euros, repayable in monthly instalments, bearing interest at annual rates of 0.7% to 2.0%, maturing at different dates between December 2018 and August 2022
|
716
|
828
|
||||||
Loans, secured by the universality of the assets of
a subsidiary, denominated in euros, repayable in monthly or quarterly instalments, bearing interest at annual rates of 1.1% to 2.9%, maturing at different dates between March 2020 and July 2022
|
2,002
|
2,264
|
||||||
7,993
|
8,828
|
|||||||
Current portion of long-term debt
|
2,808
|
2,921
|
||||||
$
|
5,185
|
$
|
5,907
|
As at
November 30,
2018
|
As at
August 31,
2018
|
|||||||
No later than one year
|
$
|
2,808
|
$
|
2,921
|
||||
Later than one year and no later than five years
|
4,966
|
5,745
|
||||||
Later than five years
|
219
|
162
|
||||||
$
|
7,993
|
$
|
8,828
|
6
|
Share Capital
|
Three months ended November 30, 2017
|
||||||||||||||||||||
Multiple voting shares
|
Subordinate voting shares
|
|||||||||||||||||||
Number
|
Amount
|
Number
|
Amount
|
Total
amount |
||||||||||||||||
Balance as at September 1, 2017
|
31,643,000
|
$
|
1
|
23,068,777
|
$
|
90,410
|
$
|
90,411
|
||||||||||||
Redemption of restricted share units
|
−
|
−
|
155,619
|
−
|
−
|
|||||||||||||||
Reclassification of stock-based compensation costs to share capital upon
exercise of stock awards
|
−
|
−
|
−
|
598
|
598
|
|||||||||||||||
Balance as at November 30, 2017
|
31,643,000
|
$
|
1
|
23,224,396
|
$
|
91,008
|
$
|
91,009
|
Three months ended November 30, 2018
|
||||||||||||||||||||
Multiple voting shares
|
Subordinate voting shares
|
|||||||||||||||||||
Number
|
Amount
|
Number
|
Amount
|
Total
amount |
||||||||||||||||
Balance as at September 1, 2018
|
31,643,000
|
$
|
1
|
23,472,995
|
$
|
91,936
|
$
|
91,937
|
||||||||||||
Redemption of restricted share units
|
−
|
−
|
176,729
|
−
|
−
|
|||||||||||||||
Reclassification of stock-based compensation costs to share capital upon
exercise of stock awards
|
−
|
−
|
−
|
643
|
643
|
|||||||||||||||
Balance as at November 30, 2018
|
31,643,000
|
$
|
1
|
23,649,724
|
$
|
92,579
|
$
|
92,580
|
7
|
Statements of Earnings
|
Three months ended
November 30,
|
||||||||
2018
|
2017
|
|||||||
Test and measurement
|
$
|
49,764
|
$
|
50,186
|
||||
Service assurance, systems and services
|
19,416
|
12,968
|
||||||
Foreign exchange gains on forward exchange contracts
|
21
|
237
|
||||||
Total sales for the period
|
$
|
69,201
|
$
|
63,391
|
Three months ended
November 30,
|
||||||||
2018
|
2017
|
|||||||
Gross research and development expenses
|
$
|
17,225
|
$
|
13,063
|
||||
Research and development tax credits
|
(2,001
|
)
|
(1,811
|
)
|
||||
Net research and development expenses for the period
|
$
|
15,224
|
$
|
11,252
|
Three months ended
November 30,
|
||||||||
2018
|
2017
|
|||||||
Inventory write-down for the period
|
$
|
1,045
|
$
|
703
|
Three months ended
November 30,
|
||||||||
2018
|
2017
|
|||||||
Cost of sales
|
||||||||
Depreciation of property, plant and equipment
|
$
|
524
|
$
|
472
|
||||
Amortization of intangible assets
|
2,523
|
911
|
||||||
3,047
|
1,383
|
|||||||
Selling and administrative expenses
|
||||||||
Depreciation of property, plant and equipment
|
264
|
164
|
||||||
Amortization of intangible assets
|
232
|
112
|
||||||
496
|
276
|
|||||||
Net research and development expenses
|
||||||||
Depreciation of property, plant and equipment
|
641
|
518
|
||||||
Amortization of intangible assets
|
185
|
96
|
||||||
826
|
614
|
|||||||
$
|
4,369
|
$
|
2,273
|
|||||
Depreciation of property, plant and equipment
|
$
|
1,429
|
$
|
1,154
|
||||
Amortization of intangible assets
|
2,940
|
1,119
|
||||||
$
|
4,369
|
$
|
2,273
|
Three months ended
November 30,
|
||||||||
2018
|
2017
|
|||||||
Salaries and benefits
|
$
|
35,741
|
$
|
29,622
|
||||
Restructuring charges
|
2,226
|
−
|
||||||
Stock-based compensation costs
|
418
|
402
|
||||||
Total employee compensation for the period
|
$
|
38,385
|
$
|
30,024
|
Three months ended
November 30,
|
||||||||
2018
|
2017
|
|||||||
Cost of sales
|
$
|
36
|
$
|
36
|
||||
Selling and administrative expenses
|
284
|
276
|
||||||
Net research and development expenses
|
98
|
90
|
||||||
Total stock-based compensation for the period
|
$
|
418
|
$
|
402
|
Three months ended
November 30,
|
||||||||
2018
|
2017
|
|||||||
Cost of sales
|
$
|
287
|
$
|
−
|
||||
Selling and administrative expenses
|
397
|
−
|
||||||
Net research and development expenses
|
2,057
|
−
|
||||||
Income taxes
|
3
|
−
|
||||||
Total restructuring charges for the period
|
$
|
2,744
|
$
|
−
|
8
|
Income Taxes
|
Three months ended
November 30,
|
||||||||
2018
|
2017
|
|||||||
Income tax provision (recovery) at combined Canadian federal and
provincial statutory tax rate (27%)
|
$
|
(1,573
|
)
|
$
|
1,193
|
|||
Increase (decrease) due to:
|
||||||||
Foreign income taxed at different rates
|
234
|
(103
|
)
|
|||||
Non-deductible loss (non-taxable income)
|
100
|
(54
|
)
|
|||||
Non-deductible expenses
|
226
|
381
|
||||||
Foreign exchange effect of translation of foreign subsidiaries
|
(160
|
)
|
(92
|
)
|
||||
Utilization of previously unrecognized deferred income tax assets
|
(84
|
)
|
(244
|
)
|
||||
Unrecognized deferred income tax assets on temporary deductible
differences and unused tax losses
|
2,553
|
1,035
|
||||||
Other
|
345
|
(376
|
)
|
|||||
Income tax provision for the period
|
$
|
1,641
|
$
|
1,740
|
Three months ended
November 30,
|
||||||||
2018
|
2017
|
|||||||
Current
|
$
|
1,670
|
$
|
1,980
|
||||
Deferred
|
(29
|
)
|
(240
|
)
|
||||
$
|
1,641
|
$
|
1,740
|
9
|
Earnings per Share
|
Three months ended
November 30,
|
||||||||
2018
|
2017
|
|||||||
Basic weighted average number of shares outstanding (000’s)
|
55,184
|
54,805
|
||||||
Plus dilutive effect of (000’s):
|
||||||||
Restricted share units
|
−
|
813
|
||||||
Deferred share units
|
−
|
175
|
||||||
Diluted weighted average number of shares outstanding
(000’s)
|
55,184
|
55,793
|
||||||
Stock awards excluded from the calculation of the diluted
weighted average number of shares outstanding because their exercise price was greater than the average market price of the common shares, or their inclusion would be antidilutive (000’s)
|
1,721
|
124
|
Three months ended
November 30,
|
Three months ended
November 30,
|
|||||||||||||||
2018
|
2017
|
2018
|
2017
|
|||||||||||||
Sales
|
$
|
69,201
|
$
|
63,391
|
100.0
|
%
|
100.0
|
%
|
||||||||
Cost of sales (1)
|
28,897
|
23,289
|
41.8
|
36.7
|
||||||||||||
Selling and administrative
|
26,375
|
23,193
|
38.1
|
36.6
|
||||||||||||
Net research and development
|
15,224
|
11,252
|
22.0
|
17.8
|
||||||||||||
Depreciation of property, plant and equipment
|
1,429
|
1,154
|
2.1
|
1.8
|
||||||||||||
Amortization of intangible assets
|
2,940
|
1,119
|
4.2
|
1.8
|
||||||||||||
Change in fair value of cash contingent consideration
|
–
|
(155
|
)
|
–
|
(0.2
|
)
|
||||||||||
Interest and other expense
|
377
|
338
|
0.5
|
0.5
|
||||||||||||
Foreign exchange gain
|
(215
|
)
|
(1,218
|
)
|
(0.3
|
)
|
(1.9
|
)
|
||||||||
Earnings (loss) before income taxes
|
(5,826
|
)
|
4,419
|
(8.4
|
)
|
6.9
|
||||||||||
Income taxes
|
1,641
|
1,740
|
2.4
|
2.7
|
||||||||||||
Net earnings (loss) for the period (2)
|
$
|
(7,467
|
)
|
$
|
2,679
|
(10.8
|
)%
|
4.2
|
%
|
|||||||
Basic and diluted net earnings (loss) per share
|
$
|
(0.14
|
)
|
$
|
0.05
|
|||||||||||
Other selected information:
|
||||||||||||||||
Gross margin before depreciation and amortization (3)
|
$
|
40,304
|
$
|
40,102
|
58.2
|
%
|
63.3
|
%
|
||||||||
Research and development:
|
||||||||||||||||
Gross research and development
|
$
|
17,225
|
$
|
13,063
|
24.9
|
%
|
20.6
|
%
|
||||||||
Restructuring charges included in:
|
||||||||||||||||
Cost of sales
|
$
|
287
|
$
|
–
|
0.4
|
%
|
–
|
%
|
||||||||
Selling and administrative expenses
|
$
|
397
|
$
|
–
|
0.6
|
%
|
–
|
%
|
||||||||
Net research and development expenses
|
$
|
2,057
|
$
|
–
|
3.0
|
%
|
–
|
%
|
||||||||
Income taxes
|
$
|
3
|
$
|
–
|
–
|
%
|
–
|
%
|
||||||||
Adjusted EBITDA (3, 4)
|
$
|
2,728
|
$
|
6,059
|
3.9
|
%
|
9.6
|
%
|
(1)
|
Cost of sales is exclusive of depreciation and amortization, shown separately.
|
(2)
|
Include net loss from Astellia of $5.1 million for the three months ended November 30, 2018 (nil in
2017).
|
(3)
|
Refer to page 42 for non-IFRS measures.
|
(4)
|
Astellia negatively impacted the adjusted EBITDA by $2.3 million or 3.3% of sales for the three
months ended November 30, 2018 (nil in 2017)
|
Three months ended
November 30,
|
||||||||
2018
|
2017
|
|||||||
Test and measurement
|
$
|
49,764
|
$
|
50,186
|
||||
Service assurance, systems and services
|
19,416
|
12,968
|
||||||
69,180
|
63,154
|
|||||||
Foreign exchange gains on forward exchange contracts
|
21
|
237
|
||||||
Total sales
|
$
|
69,201
|
$
|
63,391
|
Three months ended
November 30,
|
||||||||
2018
|
2017
|
|||||||
Test and measurement
|
$
|
63,996
|
$
|
52,854
|
||||
Service assurance, systems and services
|
17,221
|
12,788
|
||||||
81,217
|
65,642
|
|||||||
Foreign exchange gains on forward exchange contracts
|
21
|
237
|
||||||
Total bookings
|
$
|
81,238
|
$
|
65,879
|
Three months ended
November 30,
|
||||||||
2018
|
2017
|
|||||||
Americas
|
51
|
%
|
53
|
%
|
||||
Europe, Middle-East and Africa (EMEA)
|
33
|
23
|
||||||
Asia-Pacific (APAC)
|
16
|
24
|
||||||
100
|
%
|
100
|
%
|
(1)
|
Refer to page 44 for quarterly sales by product lines for fiscal 2018.
|
Increase in bank loan
|
$
|
11,257
|
||
Cash flows used by operating activities
|
(2,475
|
)
|
||
Purchases of capital assets
|
(2,882
|
)
|
||
Repayment of long-term debt
|
(717
|
)
|
||
Unrealized foreign exchange loss on cash and short-term investments
|
(160
|
)
|
||
$
|
5,023
|
Long-term
debt
|
Operating
leases
|
Licensing
agreements
|
Total
|
|||||||||||||
No later than one year
|
$
|
2,808
|
$
|
3,041
|
$
|
1,116
|
$
|
6,965
|
||||||||
Later than one year and no later than five years
|
4,966
|
8,531
|
1,964
|
15,461
|
||||||||||||
Later than five years
|
219
|
293
|
‒
|
512
|
||||||||||||
$
|
7,993
|
$
|
11,865
|
$
|
3,080
|
$
|
22,938
|
Expiry dates
|
Contractual
amounts
|
Weighted average
contractual
forward rates
|
||||||
December 2018 to August 2019
|
$
|
22,200,000
|
1.2969
|
|||||
September 2019 to August 2020
|
19,500,000
|
1.2795
|
||||||
September 2020 to August 2021
|
5,100,000
|
1.2751
|
||||||
Total
|
$
|
46,800,000
|
1.2873
|
Expiry dates
|
Contractual
amounts
|
Weighted average contractual
forward rate
|
||||||
December 2018 to August 2019
|
$
|
4,000,000
|
68.77
|
As reported
as at
August 31, 2018
|
Adjustments
|
As adjusted
as at
September 1, 2018
|
||||||||||
Accounts receivables – Trade
|
$
|
47,273
|
$
|
(303
|
)
|
$
|
46,970
|
|||||
Income taxes and tax credits recoverable
|
$
|
4,790
|
$
|
50
|
$
|
4,840
|
||||||
Total assets
|
$
|
284,544
|
$
|
(253
|
)
|
$
|
284,291
|
|||||
Retained earnings
|
$
|
114,906
|
$
|
(253
|
)
|
$
|
114,653
|
|||||
Shareholders’ equity
|
$
|
177,921
|
$
|
(253
|
)
|
$
|
177,668
|
Financial assets
|
Classification – IAS 39
|
Classification – IFRS 9
|
Cash
|
Loans and receivables
|
Amortized cost
|
Short-term investments
|
Available for sale
|
Fair value through other comprehensive income
|
Accounts receivable
|
Loans and receivables
|
Amortized cost
|
Other assets
|
Loans and receivables
|
Amortized cost
|
Forward exchange contracts
|
Derivatives used for hedging
|
Derivatives used for hedging
|
Bank loan
|
Other financial liabilities
|
Amortized cost
|
Accounts payable and accrued liabilities
|
Other financial liabilities
|
Amortized cost
|
Other liabilities
|
Other financial liabilities
|
Amortized cost
|
Long-term debt
|
Other financial liabilities
|
Amortized cost
|
Forward exchange contracts
|
Derivatives used for hedging
|
Derivatives used for hedging
|
Three months ended
November 30,
|
||||||||
2018
|
2017
|
|||||||
IFRS sales
|
$
|
69,201
|
$
|
63,391
|
||||
Acquisition-related deferred revenue fair value adjustment
|
864
|
–
|
||||||
Non-IFRS sales
|
$
|
70,065
|
$
|
63,391
|
Three months ended
November 30,
|
||||||||
2018
|
2017
|
|||||||
IFRS net earnings (loss) for the period
|
$
|
(7,467
|
)
|
$
|
2,679
|
|||
Add (deduct):
|
||||||||
Depreciation
|
1,429
|
1,154
|
||||||
Amortization
|
2,940
|
1,119
|
||||||
Interest and other expense
|
377
|
338
|
||||||
Income taxes
|
1,641
|
1,740
|
||||||
Stock-based compensation costs
|
418
|
402
|
||||||
Restructuring charges
|
2,741
|
–
|
||||||
Change in fair value of cash contingent consideration
|
–
|
(155
|
)
|
|||||
Acquisition-related deferred revenue fair value adjustment
|
864
|
–
|
||||||
Foreign exchange gain
|
(215
|
)
|
(1,218
|
)
|
||||
Adjusted EBITDA for the period (1, 2)
|
$
|
2,728
|
$
|
6,059
|
||||
Adjusted EBITDA in percentage of sales
|
3.9
|
%
|
9.6
|
%
|
(1)
|
Astellia negatively impacted adjusted EBITDA by $2.3 million, or 3.3% of sales in the three months
ended November 30, 2018 (nil in 2017).
|
(2)
|
Includes acquisition-related costs of $0.7 million in the three months ended November 30, 2017 (nil
in 2018).
|
Quarters ended
|
||||||||||||||||
November 30,
2018
|
August 31,
2018
|
May 31,
2018
|
February 28,
2018
|
|||||||||||||
Sales
|
$
|
69,201
|
$
|
69,216
|
$
|
72,217
|
$
|
64,722
|
||||||||
Cost of sales (2)
|
$
|
28,897
|
$
|
27,426
|
$
|
28,963
|
$
|
25,326
|
||||||||
Net loss
|
$
|
(7,467
|
)
|
$
|
(3,951
|
)
|
$
|
(5,970
|
)
|
$
|
(4,660
|
)
|
||||
Basic and diluted net loss per share
|
$
|
(0.14
|
)
|
$
|
(0.07
|
)
|
$
|
(0.11
|
)
|
$
|
(0.08
|
)
|
Quarters ended
|
||||||||||||||||
November 30,
2017
|
August 31,
2017
|
May 31,
2017
|
February 28,
2017
|
|||||||||||||
Sales
|
$
|
63,391
|
$
|
62,981
|
$
|
58,505
|
$
|
60,030
|
||||||||
Cost of sales (2)
|
$
|
23,289
|
$
|
23,972
|
$
|
24,555
|
$
|
22,989
|
||||||||
Net earnings (loss)
|
$
|
2,679
|
$
|
844
|
$
|
(4,304
|
)
|
$
|
1,008
|
|||||||
Basic and diluted net earnings (loss) per share
|
$
|
0.05
|
$
|
0.02
|
$
|
(0.08
|
)
|
$
|
0.02
|
(1)
|
Quarterly financial information has been derived from our condensed unaudited interim consolidated
financial statements, which are prepared in accordance with IFRS, as issued by the IASB, applicable to the preparation of interim financial statements, including IAS 34, “Interim Financial Reporting”. The presentation currency is the US dollar, which differs from the functional currency of the company (Canadian dollar).
|
(2)
|
The cost of sales is exclusive of depreciation and amortization.
|
Quarters ended
|
||||||||||||||||||||
August 31,
2018
|
May 31,
2018
|
February 28,
2018
|
November 30,
2017
|
Total
|
||||||||||||||||
Test and measurement
|
$
|
47,489
|
$
|
49,864
|
$
|
49,884
|
$
|
50,186
|
$
|
197,423
|
||||||||||
Service assurance, systems and services
|
21,649
|
22,174
|
14,457
|
12,968
|
71,248
|
|||||||||||||||
Foreign exchange gains on forward exchange contracts
|
78
|
179
|
381
|
237
|
875
|
|||||||||||||||
Total sales
|
$
|
69,216
|
$
|
72,217
|
$
|
64,722
|
$
|
63,391
|
$
|
269,546
|
1. |
Review: I have reviewed
the interim financial report and interim MD&A (together, the “interim filings”) of EXFO Inc. (the “issuer”) for the
interim period ended November 30, 2018.
|
2. |
No misrepresentation:
Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary
to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.
|
3. |
Fair presentation:
Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the
financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.
|
4. |
Responsibility: The
issuer's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as those terms are
defined in Regulation 52-109 respecting Certification of Disclosure in Issuer’s Annual and Interim Filings (c. V-1.1, r. 27), for the issuer.
|
5. |
Design: Subject to the
limitations, if any, described in paragraphs 5.2 and 5.3, the issuer's other certifying officer and I have, as at the end of the period covered by the interim filings
|
(a) |
designed DC&P, or caused it to be designed under our supervision, to provide reasonable assurance that
|
(i) |
material information relating to the issuer is made known to us by others, particularly during the period in which the interim
filings are being prepared; and
|
(ii) |
information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it
under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and
|
(b) |
designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with the issuer's GAAP.
|
5.1 |
Control framework: The
control framework the issuer's other certifying officer and I used to design the issuer's ICFR is the Internal Control –
Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).
|
5.2 |
N/A
|
5.3 |
N/A
|
6. |
Reporting changes in ICFR:
The issuer has disclosed in its interim MD&A any change in the issuer's ICFR that occurred during the period beginning on September 1, 2018 and ended on November 30, 2018 that has materially affected, or is
reasonably likely to materially affect, the issuer's ICFR.
|
1. |
Review: I have
reviewed the interim financial report and interim MD&A (together, the “interim filings”) of EXFO Inc. (the “issuer”)
for the interim period ended November 30, 2018.
|
2. |
No misrepresentation:
Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is
necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.
|
3. |
Fair presentation:
Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects
the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.
|
4. |
Responsibility: The
issuer's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as those terms are
defined in Regulation 52-109 respecting Certification of Disclosure in Issuer’s Annual and Interim Filings (c. V-1.1, r. 27), for the issuer.
|
5. |
Design: Subject to
the limitations, if any, described in paragraphs 5.2 and 5.3, the issuer's other certifying officer and I have, as at the end of the period covered by the interim filings
|
(a) |
designed DC&P, or caused it to be designed under our supervision, to provide reasonable assurance that
|
(i) |
material information relating to the issuer is made known to us by others, particularly during the period in which the interim
filings are being prepared; and
|
(ii) |
information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by
it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and
|
(b) |
designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with the issuer's GAAP.
|
5.1 |
Control framework:
The control framework the issuer's other certifying officer and I used to design the issuer's ICFR is the Internal Control –
Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).
|
5.2 |
N/A
|
5.3 |
N/A
|
6. |
Reporting changes in ICFR:
The issuer has disclosed in its interim MD&A any change in the issuer's ICFR that occurred during the period beginning on September 1, 2018 and ended on November 30, 2018 that has materially affected, or is
reasonably likely to materially affect, the issuer's ICFR.
|